Emerging Markets Clinical Trials

Africa

Emerging Markets Clinical Trials

$995.00

Despite maintaining regional offices within Africa, many major drug and device manufacturers frequently overlook the continent when sponsoring clinical studies. Cultural barriers, political upheaval and uneven infrastructure are certainly causes for the lack of interest. But Africa offers tremendous expertise and opportunity for drug and device companies looking for cost-effective study sites and appropriate patient drug market populations.

As challenging as Africa may seem, drug companies have made commitments to improve healthcare across the continent, and these companies' clinical development strategies go hand-in-hand with that improvement. In coming years, the drug market and device industries will greatly expand their clinical development presence in Africa, mainly in South Africa and a select few North African nations.

Make sure that your clinical strategy team has all the knowledge available about the growth opportunities in these countries. Africa presents a unique profile that interests many life sciences companies.

  • Description
  • Additional information

REPORT HIGHLIGHTS

 

Emerging Markets Clinical Trials: Africa

  • Publication Date: November 2010
  • Pages: 117
  • Chapters: 2
  • Metrics: 300+
  • Charts/Graphics: 74
  • Profiles: 8

Data split by:

  • South Africa
  • Emerging North African countries
Reason to Buy

Of all emerging locations or regions, Africa has arguably the least access to quality care, ensuring a steady stream of dedicated patients to fill clinical trials Africa enrollments. In addition, the most advanced nations offer highly diverse patient populations that will translate well for submissions in the US and EU. Many major European companies are located just across the Mediterranean from North Africa, making travel and communication easier than in Latin America, for example. For American companies, Africa is much closer than Asia.

Report Features

Africa presents a unique profile that interests many multinational life sciences companies. If the following benefits outweigh the challenges for a clinical team — as they often do — trial sponsors will find value in Africa:
– Patient access analysis
– Geographic analysis
– Regulatory analysis
– Clinical utilization findings

Target Audience

Executives, directors, and managers involved in the following areas should consider purchasing this report:
– Clinical development
– Site/Trial Management
– Patient Recruitment
– Strategic planning groups
– Contract Research Organizations (CROs)
– Strategic Planning

Chapter Example

Africa presents a unique profile that interests many multinational life sciences companies. As challenging as Africa may seem, drug companies have made commitments to improve healthcare across the continent, and these companies’ clinical development strategies go hand-in-hand with that improvement. In coming years, the drug and device industries will greatly expand their clinical development presence in Africa, mainly in South Africa and a select few North African nations.